Shares of struggling telehealth company Teladoc Health (TDOC 3.57%) collapsed after it recently released earnings for the first quarter of 2022. After shooting to roughly $300 per share in early 2021, the stock sits at just under $40, a staggering decline of more than 80%.
Will Teladoc ever recover?
Despite the stock's steady decline over the past year, Teladoc Health still holds a promising future due to its disruptive model. According to Tulane University School of Public Health and Tropical Medicine, Telemedicine is here to stay for the foreseeable future.
Why did Teladoc go down?
Teladoc stock fell in after-hours trading Tuesday after the telehealth giant posted fourth-quarter earnings, despite results exceeding Wall Street's expectations on profit and revenue.
Will Teladoc ever be profitable?
The telehealth giant isn't yet profitable and reported a loss of $84.3 million in the third quarter of 2021, deeper than its year-prior loss of $36 million. Shares of Teladoc stock fell 6.2% on Monday as of 10:47 a.m. in New York.
Is Teladoc still a good buy?
Teladoc Health, Inc. (NYSE:TDOC) delivered a -39.02% return since the beginning of the year, while its 12-month returns are down by -67.23%. The stock closed at $55.99 per share on April 25, 2022. "Teladoc is the largest telehealth provider in the US and has recently begun to expand internationally.
Teladoc CRASHES! Is It Coming Back?
Is Teladoc undervalued?
The revenue per member was reported $2.32 in 2021, up from $1.12 in 2020. I believe Teladoc's stock price is undervalued based on relative valuation indicators. The stock's price-to-sales ratio hit below 4 in mid-March (lowest since 2016) and is trading at 5.33, while the price-to-book ratio is at 0.69.
What is the future of Teladoc stock?
First, the company expects its net loss to continue shrinking. For fiscal 2022, Teladoc projected it would report a net loss per share between $1.60 and $1.40. At this rate, Teladoc could become profitable by 2024.
Is Teladoc overvalued?
Valuation metrics show that Teladoc Health, Inc. may be overvalued. Its Value Score of D indicates it would be a bad pick for value investors. The financial health and growth prospects of TDOC, demonstrate its potential to underperform the market.
Who are Teladoc competitors?
Teladoc Health's top competitors include naviHealth, Lash Group, Amwell, 98point6, MDLIVE, Providence Service Corporation and Sharecare. Teladoc Health is a telehealth company that uses telephone and video conferencing technology to provide on-demand remote medical care via mobile devices, the internet, and video.
Is TDOC buy or sell?
The consensus among 27 Wall Street analysts covering (NYSE: TDOC) stock is to Buy TDOC stock.
Who is buying Teladoc?
Wood again purchased about 610,000 Teladoc shares via four ARK exchange-traded funds on Thursday, with most of the buying by its flagship ARK Innovation ETF, according to its daily trading update. The company is part of a group of former pandemic winners backed by Wood.
Is Teladoc an acquisition target?
As a reader, you need to bear in mind that Teladoc is an acquisition vehicle; we thus need to consider that its "struggle towards profitability" has been down to transitory costs rather than a flawed business model.
What was teladoc IPO price?
Telehealth platform company Teladoc, on Tuesday, announced that its initial public offering would be priced at $19 per share, raising $157 million, according to a Renaissance Capital post to NASDAQ.com.
What is a good debt to equity ratio?
Generally, a good debt to equity ratio is around 1 to 1.5.
Is docu a buy?
The sell-side's consensus sales increase estimate for DOCU in Q1 FY 2023 is +24.0% (versus +23.9% for management guidance); and the analysts see DocuSign generating a revenue growth of +17.6% for full-year fiscal 2023 (versus management's expectations of +17.5%).
Is Pinterest a buy Zacks?
Zacks' proprietary data indicates that Pinterest, Inc. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the PINS shares relative to the market in the next few months.
What happen to Teladoc?
Teladoc reported a loss of $41.58 per share. Analysts were expecting a loss of 60 cents per share. (Revenues came in at $565.4 million, just shy of the estimate of $568.7 million.) The jaw-dropping loss came from an impairment charge of over $6.5 billion.
Did Teladoc buy Livongo?
Teladoc, the largest virtual care company in the U.S., bought Livongo for $18.5 billion in cash and stock late 2020 in the biggest digital health deal to date. However, the merger has struggled, resulting in the large goodwill impairment charge for the Purchase, New York-based vendor.
Why did Teladoc merger with Livongo?
The merger would combine Livongo's platform for managing chronic conditions, such as diabetes and heart disease, with telemedicine. The two businesses are expected to be complementary, with Livongo's platform offering a way to keep patients engaged in between telehealth visits.
Does Cathie Wood own Teladoc?
The shares have plunged 89% since peaking in February of last year. Wood has been loading up on Teladoc. She now owns roughly 11.4% of the company across all of her ETFs.
Did Cathie Wood buy more Teladoc?
Cathie Wood bought more than $20 million worth of Teladoc as stock tanked Thursday. Ark Invest's Cathie Wood doubled down on Teladoc even as shares of one of her favorites stocks dropped 40% on Thursday.
What is Nio price target?
The 31 analysts offering 12-month price forecasts for NIO Inc have a median target of 30.38, with a high estimate of 66.84 and a low estimate of 21.94. The median estimate represents a +34.89% increase from the last price of 22.52.
